Paul Edward Kelly - 04 Apr 2022 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)

Role: Director
Signature: /s/ Paul Kelly
Issuer symbol: RLMD
Transactions as of: 04 Apr 2022
Net transactions value: -$267,995
Form type: 4
Filing time: 05 Apr 2022, 17:34:22 UTC
Previous filing: 05 Jan 2022
Next filing: 20 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RLMD	Common Stock	Options Exercise	$32,400	+10,000	+5.3%	$3.24	197,295	04 Apr 2022	Direct
transaction	RLMD	Common Stock	Sale	$300,395	-10,000	-5.1%	$30.04^*	187,295	04 Apr 2022	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RLMD	Options to purchase common stock	Options Exercise	$0	-10,000	-33%	$0.000000	20,500	04 Apr 2022	Common Stock	10,000	$3.24	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020.
F2	The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
F3	Sales prices range from $30.00 to $30.20 per share, inclusive.
F4	The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.